Invega Trinza (paliperidone palmitate) Extended-release Injectable Suspension
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
March 2016
CONTRAINDICATIONS
RISPERDAL/RISPERDAL CONSTA/INVEGA(s) is contraindicated in patients with a known...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts